Background: The MitraClip procedure was established as a therapeutic alternative to mitral
INTRODUCTION
Mitral regurgitation (MR) is the second most frequent valve disease, with an increasing prevalence in elderly (> 75 years) patients, and is related to reduced functional capacity and impaired quality of life. Transcatheter mitral valve repair (TMVR) with the MitraClip system (Abbot Vascular, Inc., Santa Clara, California) is a therapeutic alternative to mitral valve (MV) surgery in symptomatic patients with moderate to severe MR at prohibitive surgical risk [1] [2] [3] . TMVR with the MitraClip procedure can be successfully performed in patients with secondary MR (sMR) and primary MR (pMR) if mitral valve (MV) anatomy is suitable [4] . Its clinical efficacy and safety have been proven in a large number of patients [4] [5] [6] .
Acute procedural success rates are reported to be up to 99% and are followed by symptomatic improvement in about 80% of cases [7] .
A high baseline systolic pulmonary artery pressure (sPAP), a mean elevated baseline mitral valve gradient (MVG), concomitant chronic kidney disease, anemia, peripheral artery disease, and tricuspid regurgitation have been previously reported as independent predictors of poor short-term outcomes after MitraClip procedures [8, 9, 11] .
Although more than 70,000 patients have undergone MitraClip procedures to date, data on long-term outcome and durability of MR reduction are limited, and parameters predicting adverse long-term outcomes are not well defined.
The objectives of the present study were to evaluate functional and echocardiographic long-term outcomes 5 years subsequent to transcatheter edge-to-edge mitral valve repair with the MitraClip procedure in a single high-volume center and assess predictors of poor outcomes.
METHODS

Patients and endpoints
In this single-center study, consecutive patients undergoing TMVR with the MitraClip system were prospectively included. From February 2011 to February 2014 symptomatic (functional New York Heart Association [NYHA] class > II), and surgical high-risk patients with moderate-to-severe MR were evaluated for TMVR. All patients underwent TMVR following heart team judgement according to surgical high-risk (EuroSCORE II > 6%).
All patients underwent clinical and echocardiographic examinations before and 5 years after the MitraClip procedure.
According to Mitral Valve Academic Research Consortium (MVARC) definitions, the primary endpoint was defined as all-cause mortality [24] . The secondary endpoint was an improvement in functional capacity: functional NYHA class at follow-up was < II; 25% amelioration in exercise capacity (six-minute walking test [6MWT]).
The study was authorized by the local ethics committee and in accordance with the Declaration of Helsinki. All patients signed written, informed consent before study inclusion.
Echocardiography and follow-up assessment
Echocardiographic assessment before and after TMVR was done following current recommendations and guidelines which included a comprehensive echocardiography [4, 12] .
The severity of MR was graded using the radius of proximal isovelocity surface area (PISA radius), effective regurgitant orifice area (EROA), as well as vena contracta (VC) width and regurgitant volume. EROA and regurgitation volume were calculated using the semiquantitative PISA-method [13] . The echocardiographic studies were performed with a commercially available echocardiographic system (iE 33, Philips Medical Systems, Andover, Massachusetts) and echocardiography probes (X5-1, X7-2t) allowing acquisition of two-(2D) and three-dimensional (3D) data sets. sPAP was estimated from Doppler-based peak tricuspid regurgitation velocity according to use of modified Bernoulli equation (Delta-pressure: 4 × velocity) to approximate differences of pressure between right ventricle and atrium.
The echocardiographer who performed follow-up evaluation was blinded to procedural outcomes and patient characteristics. Trained personnel carried out clinical followup evaluation, unattended by the interventionalists or procedural echocardiographer.
Interventional edge-to-edge repair of MR
Procedural details of TMVR with the MitraClip system have been described previously [14, 15] . During the MitraClip procedure, acute changes of MR severity were assessed by intraprocedural transesophageal echocardiography as supposed by Foster and Wunderlich [16, 17] . Acute procedural success was defined as a reduction of MR by at least one grade having a residual MR < 2+. The number of clips required for procedural success was left to the discretion of the treating physician. Before clip release, echocardiography was performed to exclude clinically relevant MV stenosis (mean valve gradient [MVG] > 5 mmHg). 
Statistical analysis
RESULTS
Baseline data and procedural outcomes
Two hundred sixty-five consecutive, surgically high-risk patients (81.4 ± 8.1 years, 46.7% female, Logistic EuroSCORE: 19.7 ± 16.7%, 60.5% sMR) underwent TMVR with the MitraClip system, and the majority of patients (88%, n = 233) completed a 5-year follow-up including physical, laboratory and echocardiographical examinations. Patients lost to followup (n = 32) were contacted concerning life quality, complaints and hospitalization via telephone.
The baseline characteristics are presented in Table 1 . There were no differences between the groups in demographic baseline characteristics. However, at baseline, patients with sMR presented worse functional capacity (6MWT: 253.3 ± 107.7 m vs. 267.1 ± 160.2 m; p = 0.2; NYHA > III 44.2% vs. 13.8%; p = 0.06) compared to patients with pMR.
The procedure was successfully performed in 242 (91.3%) patients with implantation of more than one clip in 32% of cases. Six MitraClip procedures were aborted due to relevant MV stenosis (MVG > 5 mmHg) after clip closure. Four of those patients were treated for pMR. 13 procedures were aborted due to irreducible MR.
Of note, there was no procedural-related mortality, ten patients (23.8%) had minor bleeding, and one patient had pericardial tamponade, which could be effectively treated with pericardiocentesis. All acute complications could be successfully managed before discharge.
Overall, interventional failure rates were low, however, patients with pMR showed statistically significant higher interventional failure rates (pMR: 8.6%, sMR: 3.1%; p = 0.04). Table 2 ).
At 5-year follow-up a sustained reduction of MR (MR ≤ 2) was found in 74% of patients (sMR: 77%, pMR: 71.5%; p = 0.9). There were no significant changes in LV volumes (LVEDVsMR: 162.4 ± 56.7 mL, 154.5 ± 66.9 mL; p = 0.5; LVEDVpMR: 127.8 ± 47. and echocardiographic amelioration at follow-up and lower interventional failure rates, allcause 5-year mortality was significantly higher in sMR patients. Baseline levels of creatinine > 2 mg/dL, MVG > 1.5 mmHg and sPAP > 50 mmHg were independent predictors of the 5-year mortality and poor functional outcomes.
Survival and re-intervention rates
Mortality after TMVR with the MitraClip device has been evaluated previously in different studies. Toggweiler et al. [18] found in 75 patients, a patient mortality of 4% at 30 days, 9% at 1 year and 25% (sMR: 28%, pMR 18%) at 2 years after the MitraClip procedure.
Comparable data were presented in 304 patients by Capodanno et al. [19] (4% at 30 days, 11% at 1-year, and 19% at 2-years). The EVEREST II study found a 20% 5-year mortality without statistical difference between MR etiologies [6] .
In line with those studies, sustained MR reduction was found with improved functional capacity and quality of life 5 years after the MitraClip procedure. Although the patients in the present study were considerably older (mean age: 81 years), they had sMR more often and were in higher baseline functional NYHA classes, long-term mortality rates (16%) were comparable to the cited studies. In contrast to EVEREST II, higher mortality in patients with sMR was found despite noticeable improvement of functional capacity at follow-up. Of note, in the early EVEREST studies, echocardiographic feasibility criteria were far more restrictive, and the majority of patients were treated for pMR, which might account for different acute and long-term procedural success rates.
Higher all-cause mortality at follow-up in sMR patients was found, and might be In line with current results, they found pronouncedly worse outcomes and higher mortality in patients with secondary MR associated with worse LV remodelling and function.
Predictors of adverse outcome
Azzalini et al. [22] showed that an impaired LV function was associated with increased mortality in 77 patients with sMR one year after the MitraClip procedure. This finding is in line with the present data. A higher 5-year mortality in sMR patients with reduced baseline LV function was found (EF < 40%) compared to pMR patients with a baseline LVEF > 55%.
Another independent marker for secondary endpoint was the baseline level of creatinine (> 2 mg/dL) in the current study. This finding is supported by a study from Ohno et al. [23] . They found a significant adverse effect of concomitant chronic kidney disease on MR reduction, functional capacity (functional NYHA class), survival and frequency of re-repair in 214 patients with severe MR 1 year after the MitraClip procedure.
Toggweiler [9] (baseline MVG > 3 mmHg) and Neuss et al. (post-procedural MVG > 5 mmHg) showed a devastating impact of higher MVG on clinical outcomes and procedural success [18] . In concordance with those results, baseline MVG (> 1.5 mmHg) as an independent predictor for both primary and secondary endpoints at 5-year follow-up was found in the present study.
Moreover, Matsumoto et al. [11] found that pre-existing pulmonary hypertension was a strong predictor of higher all-cause mortality 12 months after the MitraClip procedure. The
Association between worse outcomes and advanced heart disease and symptoms have been presented by Buzzatti et al. [26] in more than 300 patients with relevant MR at 5-year followup. The cited study validates present findings; elevated baseline sPAP values are an independent predictor of (> 45 mmHg) adverse outcomes and (> 50 mmHg) all-cause mortality at 5-year follow-up.
Limitations of the study
This single-center retrospective study has several limitations. Data was reported from a single-center experience, and all echocardiographic analyses were not verified by an independent core lab. Furthermore, the 5-year follow-up was sufficiently completed in 233 (88%) patients. Because of this, the present results should be proven in multi-center studies with a larger patient collective.
CONCLUSIONS
Transcatheter mitral valve repair with MitraClip procedure was found to be safe, cause sustained MR reduction, and increase RV function during 5 years subsequent to the procedure. Despite pronounced functional and echocardiographical amelioration and lower procedural failure, sMR patients showed a higher all-cause 5-year mortality compared to patients with pMR. Elevated baseline creatinine, baseline levels of MVG and baseline sPAP were associated with poor functional outcome and high all-cause 5-year mortality. 
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